Compare BridgeBio Pharma Inc (BBIO) vs Williams-Sonoma, Inc. (WSM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs Williams-Sonoma, Inc. — how do they compare? BridgeBio Pharma Inc trades at $83.9 (market cap $16.61B), while Williams-Sonoma, Inc. trades at $250.52 (market cap $29.53B). The key difference: Williams-Sonoma, Inc. is the larger of the two by market cap, and Williams-Sonoma, Inc. pays a 1.21% dividend while BridgeBio Pharma Inc pays none. Which is the better fit depends on your goals.
| BBIO | WSM | |
|---|---|---|
Market Cap | $16.61B | $29.53B |
Sector | Health | Consumer Cyclical |
52-Week High | $90.17 | $251.81 |
52-Week Low | $47.29 | $168.64 |
Enterprise Value | $18.16B | $30.38B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.48, up 2.03% with bullish technical signals from moving averages. Despite strong revenue growth from $222M in 2024 to $502M in 2025, the company reports significant losses with a -144.39% net margin. Recent FDA acceptance for encaleret in ADH1 and Attruby's commercial expansion in ATTR-CM provide growth catalysts, though cash flow remains negative at -$111M in 2025.
The stock presents high-risk growth potential with 88% analyst buy ratings and $102.20 consensus target, but faces substantial execution risks from ongoing losses and $1.72B debt load. Success hinges on pipeline approvals and Attruby's market penetration, making it suitable for risk-tolerant investors betting on biotech breakthroughs.
Williams-Sonoma (WSM) trades at $251.81, up 1.94% today, near its 52-week high. The stock shows strong technical momentum with bullish moving averages, though RSI levels indicate overbought conditions. Fundamentally, the company maintains robust profitability with a 13.81% net income margin and has beaten earnings estimates for three consecutive quarters. A dividend of $0.76 is scheduled for payment in August 2026, reflecting shareholder returns.
WSM's outlook is supported by consistent earnings outperformance and high profitability metrics like 54.01% ROE. However, valuation multiples such as a P/E of 28.23 appear elevated relative to historical norms. Key risks include consumer discretionary spending volatility and competitive pressures in home furnishings. Analyst consensus is mixed with a $222.22 price target below the current price, suggesting cautious optimism amid rich valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About Williams-Sonoma, Inc.
With a wide retail and direct-to-consumer presence, Williams-Sonoma is a leader in the $300 billion domestic home category, focused on expanding its exposure in the B2B, marketplace, and franchise areas. Namesake Williams-Sonoma (175 stores) offers high-end cooking essentials, while Pottery Barn (189) provides casual home accessories. Brand extensions include Pottery Barn Kids (52) and PBteen. West Elm (121) is an emerging concept for young professionals, and Rejuvenation (9) offers lighting and house parts. Williams-Sonoma also has a business-to-business team that supports projects that range from residential to large-scale commercial.
Read more on WSM →
